ClinicalTrials.gg
RecruitingNCT05034172BIOMOVUpdated Apr 12, 2024

Biomarker Research in Inherited Movement Disorders

An observational study in Inherited Movement Disorders, Spinocerebellar Ataxias and Hyperkinetic Disorders, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 7 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-12.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Started Aug 2021; still recruiting 5 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
4,000
Ages
7 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Spinocerebellar Ataxias with a site in France — 5 open to participants now, 7 under way, none of them phase 3. Spinocerebellar Ataxias · France.

Started
2021
the only one that year
Observational
7 of 13
2 open now
Registered
8th of 13
by date
Lead sponsor
3 of 13
Assistance Publique - Hôpitaux de Paris

Among the 13 studies in Spinocerebellar Ataxias with a site in France, this one is the only one that started in 2021, is one of 7 observational ones, and was the 8th registered.

Spinocerebellar Ataxias

95 studies on the registry are indexed under Spinocerebellar Ataxias; 25 are open to participants now.

Browse Spinocerebellar Ataxias studies →

Open to participants now

5 of the 13 studies in Spinocerebellar Ataxias with a site in France are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 16 Spinocerebellar Ataxias studies recruiting now, 8 (50%) set no upper age limit and 3 (19%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 7 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Spinocerebellar Ataxias with a site in France, or all of them as a file.
02

Study summary

Inherited movement disorders are rare conditions, whose cumulative prevalence are in the order of 5-10/100,000 inhabitants, in most cases progressive and can lead to a significant loss of autonomy after one or more decades of evolution. They include spinocerebellar ataxias and hyperkinetic disorders (dystonias, choreas, tremor, parkinsonism and myoclonus with variable combination of those, or more complex alteration of movements). The existence of the National Reference Centre (CMR) for Rare Diseases (CMR Neurogenetics, devoted to ataxias and spastic paraparesis, dystonia and rare movement disorders and CMR Huntington, devoted to Huntington Disease) has allowed a more integrated vision of these diseases. This is illustrated, in the same family, by the occurrence of different clinical expressions of spinocerebellar ataxias and hyperkinetic disorders that share the same genetic background. Conversely, different causal mutations within the same gene may have very different ages at onset and a wide range of clinical expression, and the spectrum of new phenotypes linked to a single gene is still expanding . Many ataxia and dystonia genes are involved in similar pathways. There are numerous arguments supporting a share pathogenesis including synaptic transmission and neurodevelopment .

BIOMOV project aims to :

  1. establish the clinical spectrum and natural history of these diseases,
  2. understand the role of genetic and familial factors on the phenotype,
  3. elucidate the molecular basis of these disorders and evaluate diagnostic strategies involving molecular tools for clinical and genetic management,
  4. develop multimodal biomarkers both for physiopathological studies and for accurate measures of disease progression,
  5. develop trial ready cohorts of well characterized genetic patients,
  6. test new therapies either symptomatic or based on pathophysiological mechanisms.
Read the detailed description

Inherited movement disorders are rare conditions, whose cumulative prevalence are in the order of 5-10/100,000 inhabitants, in most cases progressive and can lead to a significant loss of autonomy after one or more decades of evolution. They include spinocerebellar ataxias and hyperkinetic disorders (dystonias, choreas, tremor, parkinsonism and myoclonus with variable combination of those, or more complex alteration of movements). The existence of the National Reference Centre (CMR) for Rare Diseases (CMR Neurogenetics, devoted to ataxias and spastic paraparesis, dystonia and rare movement disorders and CMR Huntington, devoted to Huntington Disease) has allowed a more integrated vision of these diseases. This is illustrated, in the same family, by the occurrence of different clinical expressions of spinocerebellar ataxias and hyperkinetic disorders that share the same genetic background. Conversely, different causal mutations within the same gene may have very different ages at onset and a wide range of clinical expression, and the spectrum of new phenotypes linked to a single gene is still expanding .

any ataxia and dystonia genes are involved in similar pathways. There are numerous arguments supporting a share pathogenesis including synaptic transmission and neurodevelopment .

Overall, there are a number of arguments for a shared genetic approach and biomarkers research for these inherited movement disorders:

  • Evidence from a clinico-genetic approach: A combination of several movement disorders is often observed in the same patient with causative mutation in either genetic groups of spinocerebellar degenerations, dystonias or choreas.
  • Evidence from neuroimaging: the current concept of networks disorders underlies the pathophysiology of these hyperkinetic movement disorders. Variable combination of functional and/ or structural alterations of the cerebello-thalamo-cortical, cortex-basal ganglia and corticospinal networks, and their complex interactions have been described in ataxias ,dystonia choreas and more complex disorders.
  • Genetic diagnosis: deciphering diagnosis with wide range of phenotypes Even in times of next generation sequencing covering exomes and genomes, diagnosing spinocerebellar degenerations, dystonia and other hyperkinetic disorders remains a challenge as: i) the causative gene remains to be identified for a substantial share those disorders; the pathogenicity of variants of unknown significance in known and potential novel disease genes often requires time-consuming functional analyses not available on a routine basis; ii) in many countries, including France, access to diagnostic whole exome and whole genome sequencing is still limited; iii) the proportions of abnormal expansions not seen in exome studies are frequent in spinocerebellar degenerations and need a technological development to identify them. Analysis of familial forms revealed a great heterogeneity of the phenotype within the same family in terms of age at onset, severity and clinical presentation. Moreover, this phenotypic variability is not explained only by the genetic heterogeneity but also by the underlying frequent exonic or intronic expansions of triplet or more complex repeats, and more recently by the discovery of genetic modifiers ; iv) for dystonia and hyperkinetic disorders, some of those disorders also include nonmovement disorders neurological (e.g. intellectual deficiencies, hypotonia at birth, immature motor control, deafness, visual defects) and non-neurological (dysmorphological features) symptoms and the movement disorders panels do not always include the genes involved in developmental disorders; v) among the dominantly inherited forms such as Huntington disease, the access to genetic testing procedures allows early preventive therapeutic interventions in premanifest individuals. There is a lack of clinical evaluation to tackle the efficiency of treatment and the need for biomarker development.
  • Natural history and prognosis: need for quantitative, reproducible markers, sensitive to evolution Biomarkers search is ongoing in those pathologies. They are valuable in assisting diagnosis, have prognostic value, quantify disease progression and serve as outcome parameters in clinical trials.

These elements demonstrate the need to develop quantitative tools that are easy to use, reproducible and sensitive to disease progression in order to accurately determine the natural history of the disease. This lack of systematic knowledge impedes diagnosis, patient counselling and therapy development.

Overall: Identification of the underlying gene and its pathogenic changes or variant(s) contributes to precise diagnosis, genetic counselling and follow-up. Advances in molecular genetics have highlighted the genotypic complexity, justifying the need for rigorous clinical and para-clinical evaluation to establish relevant phenotype-genotype correlations. In dystonia and in spinocerebellar degenerations attempts have been made to classify the genes involved.

Molecular genetic analysis will make it possible to specify the correlations between phenotype and genotype in order to propose rational molecular diagnostic strategies based on the frequency and nature of mutations, taking into account the phenotype. Genetic analyses will have an impact in terms of public health since they will serve as a basis for guiding requests for molecular analyses in these pathologies. In addition, recent advances in therapeutic trials will need the careful selection of participants, mostly based on biomarkers, for successful testing of new therapeutical agents. Therefore, it seems essential that this cohort of patients be supplemented by a collection of biological material for genetic research.

BIOMOV project aims to : 1) establish the clinical spectrum and natural history of these diseases, 2) understand the role of genetic and familial factors on the phenotype, 3) elucidate the molecular basis of these disorders and evaluate diagnostic strategies involving molecular tools for clinical and genetic management, 4) develop multimodal biomarkers both for physiopathological studies and for accurate measures of disease progression, 5) develop trial ready cohorts of well characterized genetic patients, 6) test new therapies either symptomatic or based on pathophysiological mechanisms.

It is crucial to be able to establish a large cohort of patients whose genotype will be specified. Follow-up of patients at different stages of the disease will make it possible to collect the natural history of the disease in a descriptive manner, with prospects for patient management, since the prognosis in terms of loss of autonomy or disability will be better specified. However, the main interest of the proposed clinical follow-up is to be able to quantitatively describe the progression of the main neurological diseases. These data are absolutely essential for the future implementation of therapeutic trials. The number of patients likely to be recruited and followed up a unique resource for such a project

03

Conditions studied

  • Inherited Movement Disorders
  • Spinocerebellar Ataxias
  • Hyperkinetic Disorders
04

Who can participate

Ages eligible
7 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

  • Patients with hyperkinetic movement disorders
  • At risk individuals (gene mutation carriers) with inherited hyperkinetic movement disorders
  • Healthy controls to allow variant classification and establish normal values for scales

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Common inclusion criteria for all participants:

    • Affiliated with a social security system or beneficiary of such a regime

Group of patients:

Any patient with inherited hyperkinetic movement disorders can be included in the study according to the following criteria:

Woman or man;

  • Clinical diagnosis of inherited hyperkinetic movement disorders with or without a genetic diagnosis
  • With or without familial history of the disease
  • Age ≥ 7 years;
  • Signed by the patient or both of holders of the parental authority for minors, or by the le;gal guardian for adults under guardianship

Group of at-risk individuals:

  • Woman or man;
  • Age ≥ 18 years old;
  • A first-degree relative of a patient with inherited hyperkinetic movement disorders
  • OR a carrier of an identified pathogenic variant or expansion in one of the pathological gene variant involved in one of these diseases;
  • Normal neurological examination; according to disease specific scales
  • Signed Informed consent by the subject or by the legal guardian for adults under guardianship

Group of healthy controls:

  • Woman or man;
  • Aged ≥ 18 years old;
  • Free of known neurological pathology;
  • No significant neurological symptoms;
  • Signed Informed consent by the subject

Common inclusion criteria for elective participant for skin (optional): - Age ≥10 ans

  • Ability to undergo a skin biopsy

Common inclusion criteria for elective participant for MRI examination (optional): - Ability to undergo a MRI.

Exclusion criteria

Exclusion Criteria:

Absolute criteria for non-inclusion for all groups:

  • Person deprived of their liberty by judicial decision

to MRI examination* (optional): metallic implant, pacemaker, artificial heart valve, brain vascular malformation, aneurysm clips, exposed by metallic fragments, artificial implants, peripheral or neuronal stimulator, insulin pump, intravenous catheter, epilepsy, metallic device, claustrophobia,

Contra-indication to skin (optional):

  • Taking anticoagulant or antiplatelet medication (see above),
  • History of hemostasis disorders,
  • Presence of hemorrhagic risk verified by a coagulation test
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
4,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • OtherClinical follow-up

    Clinical Follow-up: demographic data and history, * Retrospective interview (collection of data useful for genetic studies): -disease history (for patients only); * Family history - Neurological examination: * Diagnosis Clinical examination; * Rating scales specific to the pathology under investigation; * Cerebral MRI (optional) * Biological samples (optional)

06

What researchers measure

Primary outcomes

  1. Genetic entities among rare movement disorders: Pathology characterization (clinical spectrum) and its natural history: clinical Biomarkers

    Comparison of clinical biomarkers at different disease stages compared to controls.

    Time frame: 10 years

  2. Genetic entities among rare movement disorders: Pathology characterization (clinical spectrum) and its natural history : genetic Biomarkers

    Comparison of genetic biomarkers at different disease stages compared to controls.

    Time frame: 10 years

  3. Genetic entities among rare movement disorders: Pathology characterization (clinical spectrum) and its natural history : biological and/or imaging Biomarkers

    Comparison of biological and/or imaging biomarkers at different disease stages compared to controls.

    Time frame: 10 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2021 (actual). Primary completion is estimated for Aug 2031, 120 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2021
First posted
Sep 5, 2021
StartActual
Aug 25, 2021
Primary completionEst.
Aug 25, 2031
CompletionEst.
Aug 25, 2031
Last update
Apr 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05034172
Responsible party
Sponsor
First posted
Sep 5, 2021
Start date
Aug 25, 2021
Primary completion
Aug 25, 2031 (estimated)
Completion
Aug 25, 2031 (estimated)
Last update
Apr 12, 2024

Study contacts

Alexandra DURR, PUPH
Contact
alexandra.durr@aphp.fr
142161347 ext. +33
Mariana ATENCIO-SEGURA
Contact
mariana.atencio@icm-institute.org
142161347 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion